{"id":"W3108175435","doi":"10.1136/esmoopen-2020-001081","title":"Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Symphogen; Pfizer; Incyte; BeiGene; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Huntsman Cancer Institute; Sierra Oncology; King Abdullah International Medical Research Center; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen","keywords":"Dosing; Medicine; Phase (matter); Internal medicine; Oncology; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002371983,0.001520617,0.001755285,0.0003710991,0.0004512352,0.0007455571,0.0009590471,0.001179692,0.005734796],"category_scores_gemma":[0.001373463,0.00053336,0.0009680543,0.0005337951,0.0008343029,0.0007554474,0.0004049153,0.002354889,0.001209123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001056352,"about_ca_system_score_gemma":0.002091581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007919012,"about_ca_topic_score_gemma":0.002094817,"domain_scores_codex":[0.9994251,0.0003423113,0.00003031705,0.00007489745,0.00004772545,0.00007973537],"domain_scores_gemma":[0.9990139,0.0001689724,0.0002814323,0.00007371015,0.00008141233,0.0003805397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8265813,0.05611435,0.005171101,0.001234785,0.0007154914,0.0002785671,0.0002722576,0.001649935,0.05506776,0.000196151,0.004598977,0.04811947],"study_design_scores_gemma":[0.6352351,0.3505127,0.008215516,0.00003438558,0.0001713071,0.0002536417,0.00004252087,0.0007816889,0.002746452,0.0001135175,0.001872836,0.00002048428],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854359,0.002106465,0.001072066,0.0005504683,0.0001344359,0.006836223,0.001958253,0.0001288544,0.001777387],"genre_scores_gemma":[0.9785323,0.001401947,0.0046272,0.001344392,0.0001950812,0.0064701,0.004069508,0.00004694367,0.00331253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005734796,"threshold_uncertainty_score":0.01918483,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04774679406852019,"score_gpt":0.3900613635071492,"score_spread":0.342314569438629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}